Borgeson Blake 4

What Happened Blake Borgeson, a member of the board of directors of Recursion Pharmaceuticals (RXRX), was granted 88,424 restricted stock units (RSUs) on June 17, 2026. The Form 4 reports the award as acquired at $0.00 (transaction code A). These RSUs are compensation, not an open-market purchase or sale, and will convert to shares only upon vesting.

Key Details

• Transaction date: 2026-06-17. Filing date: 2026-06-22 (filed after the typical 2-business-day window).
• Award: 88,424 RSUs reported at $0.00 (Acquired).
• Shares owned after the transaction: not specified in the provided filing.
• Footnote: The RSUs were granted automatically under the Issuer's Outside Director Compensation Policy and vest on the earlier of June 17, 2027 or the day before the 2027 Annual Meeting, subject to continued service.
• Transaction code: A = Award/Grant.
• Timeliness: The Form 4 was filed five days after the transaction date, which is later than the usual two-business-day requirement for Form 4s.

Context RSUs are a form of equity compensation that convert into shares only when they vest; they do not represent immediately tradable stock and typically reflect standard director compensation practices rather than a direct signal of the director buying or selling shares. The filing’s late submission is notable for compliance tracking but does not by itself indicate any change in the director’s holdings or intentions.